Science：新冠病毒奥密克戎变异株亚谱系的抗体反应

顾汉现

Science：针对新冠病毒奥密克戎变异株亚谱系的免疫印迹抗体反应

针对 SARS-CoV-2 Omicron 亚系的印迹抗体反应。严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) Omicron 亚系携带明显的刺突突变，可逃避先前感染或疫苗接种诱导的抗体。混合免疫或疫苗助推器会引发针对 Omicron BA.1、BA.2、BA.2.12.1 和 BA.4/5 的血浆中和抗体，并且会在鼻粘膜诱导中和抗体。本研究结果识别出一种超强泛变体中和抗体，是临床研发的有力候选对象。本文是新冠病毒奥密克戎变异株疫苗和抗体关联医学研究论文。
(Baidu Translation: )
Science: Western blot antibody reaction against the subfamily of COVID-19 Omikron mutant
Imprinted antibody reaction against SARS CoV-2 Omicron subline. The Omicron subfamily of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) carries an obvious spike mutation, which can escape antibodies induced by previous infection or vaccination. Mixed immunization or vaccine booster will trigger plasma neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1 and BA.4/5, and will induce neutralizing antibodies in nasal mucosa. The results of this study identified a super strong pan variant neutralizing antibody, which is a strong candidate for clinical research and development. This is a research paper on the vaccine and antibody associated medicine of COVID-19 Omicron variant.
（百度翻訳： ）
Science：新型コロナウイルスオミクロン変異株のサブシステムに対する免疫印影抗体反応
SARS-CoV-2オミクロン亜系に対する印影抗体反応。重症急性呼吸器症候群コロナウイルス2（SARS-CoV-2）オミクロン亜系は明らかな突然変異を持ち、以前の感染やワクチン接種によって誘導された抗体から逃れることができる。混合免疫またはワクチンブースターは、Omicron BA.1、BA.2、BA.2.12.1、BAに対して誘発する.4/5の血漿中和抗体は、鼻粘膜に中和抗体を誘導する。本研究結果は超強汎変体中和抗体を識別し、臨床研究開発の有力候補である。本文は新型コロナウイルスオミクロン変異株ワクチンと抗体関連医学研究論文である。

领研网

2022/11/21

论文
论文标题：Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
作者：Young-Jun Park, Dora Pinto, Alexandra C. Walls, Zhuoming Liu, Anna De Marco, Fabio Benigni, Fabrizia Zatta, Chiara Silacci-Fregni, Jessica Bassi, Kaitlin R. Sprouse, Amin Addetia, John E. Bowen, Cameron Stewart, Martina Giurdanella, Christian Saliba, Barbara Guarino, Michael A. Schmid, Nicholas M. Franko, Jennifer K. Logue, Ha V. Dang, Kevin Hauser, Julia di Iulio, William Rivera, Gretja Schnell, Anushka Rajesh, Jiayi Zhou, Nisar Farhat, Hannah Kaiser, Martin Montiel-Ruiz, Julia Noack, Florian A. Lempp, Javier Janer, Rana Abdelnabi, Piet Maes, Paolo Ferrari, Alessandro Ceschi, Olivier Giannini, Guilherme Dias de Melo, Lauriane Kergoat, Hervé Bourhy, Johan Neyts, Leah Soriaga, Lisa A. Purcell, Gyorgy Snell, Sean P. J. Whelan, Antonio Lanzavecchia, Herbert W. Virgin, Luca Piccoli, Helen Y. Chu, Matteo Samuele Pizzuto, Davide Corti, David Veesler

期刊：Science
发表时间：2022/11/11
数字识别码：10.1126/science.adc9127
摘要：
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant–neutralizing antibody that is a strong candidate for clinical development.

所属学科：
病毒学

（导读 阿金）本研究表明混合免疫力或者疫苗增强针催生针对新冠病毒奥密克戎变异株BA.1，BA.2，BA.2.12.1与BA.4/5的血浆中和抗体，突破性感染而非疫苗会诱导鼻黏膜中的中和抗体生成。大部分抗体与免疫印迹相一致衍生自记忆性B细胞或者奥密克戎突破性病例的血浆细胞。研究结果识别出一种超强泛变体中和抗体，是临床研发的有力候选对象。

文章标签
混合免疫力
疫苗增强针
新冠病毒
奥密克戎变异株
血浆中和抗体

https://www.science.org/doi/10.1126/science.adc9127

https://www.linkresearcher.com/t ... 2-80a6-02b4b804c4fc



华成旅行社  欢迎来电咨询：

电话：03-3833-9823  / 03-5688-1863
FAX ：03-3833-9873  / 03-3834-5891

SOFTBANK电话：080-3416-2275   担当：小郭  微信号：08034162275
SOFTBANK电话：090-2172-4325   担当：小于  微信号：TYOSCL4325
SOFTBANK电话：080-3398-4387   担当：小李  微信号：huacheng4387
SOFTBANK电话：080-3523-4388   担当：小何  微信号：huacheng602
SOFTBANK电话：080-3084-4389   担当：小马  微信号：huacheng858

http://www.kaseisyoji.com/forum.php?mod=forumdisplay&fid=10